Establishing reliable islet potency assay is a critical and unmet issue for clinical islet transplantation. Recently, we reported that islets contained high levels of high mobility group box 1 (HMGB1) and damaged islets released HMGB1 in a mouse model. In this study, we hypothesized that the amount of released HMGB1 could reflect the degree of islet damage, and could predict the outcome of islet transplantation. Four groups of damaged mouse islets and three groups of damaged human islets were generated by hypoxic conditions. These islets were assessed by in vivo (transplantation) and in vitro (released HMGB1 levels, released C-peptide levels, PI staining, TUNEL staining, ATP/DNA, and glucose-stimulated insulin release test) assays. In addition, the ability of each assay to distinguish between noncured (n = 13) and cured (n = 7) mice was assessed. The curative rates of STZ-diabetic mice after receiving control, hypoxia-3h, hypoxia6h, and hypoxia-24h mouse islets were 100%, 40%, 0%, and 0%, respectively. Only amounts of released HMGB1 and ratio of PI staining significant increased according to the degree of damages in both human and mouse islets. In terms of predictability of curing diabetic mice, amounts of released HMGB1 showed the best sensitivity (100%), specificity (100%), positive (100%), and negative predictive values (100%) among all the assays. The amount of released HMGB1 reflected the degree of islet damage and correlated with the outcome of islet transplantation in mice. Hence, released HMGB1 levels from islets should be a useful marker to evaluate the potency of isolated islets.Key words: High mobility group box 1 (HMGB1); Islet; Transplantation; Potency assay; Hypoxia
INTRODUCTIONcompleted within hours) (20). Development of such an assay has been mandated by the US Food and Drug Administration (34). Islet transplantation is a promising therapy for type 1 diabetes mellitus (26) and is preferred by patients over Currently, the in vivo islet transplantation assay using diabetic mice is thought to most reliably correlate with insulin injection therapy (6). However, major issues still prevent the use of islet transplantation as a standard therclinical islet transplantation (20). However, results from this assay can be obtained only after several days and apy (10,27), including limitations of the current potency assays (20). The potency assay for islet characterization therefore cannot be used for islet prerelease testing. To develop a potency assay for an islet prerelease test, the prior to clinical transplantation should be reliable, operator independent, reproducible, and transferable to other most important endpoint is the correlation between the results of the in vitro potency assay and the in vivo laboratories (20). It should also be able to work with relatively small yet representative islet numbers without potency assay using a transplantation model. Currently, the cell membrane integrity test (2), ATP assay (4,8,29), requiring islet handpicking (which may bias the results) and should be able to pr...